Raras
Buscar doenças, sintomas, genes...
Neoplasias endócrinas múltiplas tipo 1
ORPHA:652CID-10 · D44.8CID-11 · 2F7A.0OMIM 131100DOENÇA RARA

Síndrome de predisposição tumoral autossômica dominante causada por variantes patogênicas no gene MEN1, caracterizada por um risco aumentado de tumores das glândulas paratireoides, glândula pituitária e tumores neuroendócrinos do intestino anterior (mais comumente células das ilhotas pancreáticas).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Síndrome de predisposição tumoral autossômica dominante causada por variantes patogênicas no gene MEN1, caracterizada por um risco aumentado de tumores das glândulas paratireoides, glândula pituitária e tumores neuroendócrinos do intestino anterior (mais comumente células das ilhotas pancreáticas).

Pesquisas ativas
8 ensaios
192 total registrados no ClinicalTrials.gov
Publicações científicas
2.379 artigos
Último publicado: 2026 May

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
3.3
Europe
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: D44.8
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
19 sintomas
🫃
Digestivo
10 sintomas
🦴
Ossos e articulações
4 sintomas
🫘
Rins
3 sintomas
🧬
Pele e cabelo
2 sintomas
🫁
Pulmão
1 sintomas

+ 45 sintomas em outras categorias

Características mais comuns

90%prev.
Hiperplasia de paratireoide
Muito frequente (99-80%)
90%prev.
Comprometimento das atividades da vida diária
Muito frequente (99-80%)
90%prev.
Hiperparatireoidismo primário
Muito frequente (99-80%)
90%prev.
Angiofibromas
Muito frequente (99-80%)
90%prev.
Hipercalcemia
Muito frequente (99-80%)
55%prev.
Libido masculina diminuída
Frequente (79-30%)
86sintomas
Muito frequente (5)
Frequente (18)
Ocasional (38)
Muito raro (14)
Sem dados (11)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 86 características clínicas mais associadas, ordenadas por frequência.

Hiperplasia de paratireoideParathyroid hyperplasia
Muito frequente (99-80%)90%
Comprometimento das atividades da vida diáriaImpairment of activities of daily living
Muito frequente (99-80%)90%
Hiperparatireoidismo primárioPrimary hyperparathyroidism
Muito frequente (99-80%)90%
Angiofibromas
Muito frequente (99-80%)90%
HipercalcemiaHypercalcemia
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico2.379PubMed
Últimos 10 anos200publicações
Pico202598 papers
Linha do tempo
2026Hoje · 2026🧪 1972Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

3 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant, Not applicable.

MEN1MeninDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. Binds to the TERT promoter and represses telomerase expression. Plays a role in TGFB1-mediated inhibition of cell-proliferation, possibly regulating SMAD3 transcriptional activity. Represses JUND-mediated transcriptional activation on AP1 sites, as well as that mediated by NFKB subunit RELA. Positively regulates

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (4)
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcriptionDeactivation of the beta-catenin transactivating complexFormation of the beta-catenin:TCF transactivating complexFormation of WDR5-containing histone-modifying complexes
MECANISMO DE DOENÇA

Familial multiple endocrine neoplasia type I

Autosomal dominant disorder characterized by tumors of the parathyroid glands, gastro-intestinal endocrine tissue, the anterior pituitary and other tissues. Cutaneous lesions and nervous-tissue tumors can exist. Prognosis in MEN1 patients is related to hormonal hypersecretion by tumors, such as hypergastrinemia causing severe peptic ulcer disease (Zollinger-Ellison syndrome, ZES), primary hyperparathyroidism, and acute forms of hyperinsulinemia.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
45.1 TPM
Tireoide
43.2 TPM
Cérebro - Hemisfério cerebelar
40.2 TPM
Fibroblastos
37.9 TPM
Baço
35.0 TPM
OUTRAS DOENÇAS (7)
multiple endocrine neoplasia type 1pituitary gigantismnull pituitary adenomaprolactin-producing pituitary gland adenoma
HGNC:7010UniProt:O00255
CDKN1BCyclin-dependent kinase inhibitor 1BCandidate gene tested inModerado
FUNÇÃO

Important regulator of cell cycle progression. Inhibits the kinase activity of CDK2 bound to cyclin A, but has little inhibitory activity on CDK2 bound to SPDYA (PubMed:28666995). Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1-CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its ph

LOCALIZAÇÃO

NucleusCytoplasmEndosome

VIAS BIOLÓGICAS (10)
Cyclin D associated events in G1Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)SCF(Skp2)-mediated degradation of p27/p21TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle ArrestDNA Damage/Telomere Stress Induced Senescence
MECANISMO DE DOENÇA

Multiple endocrine neoplasia 4

Multiple endocrine neoplasia (MEN) syndromes are inherited cancer syndromes of the thyroid. MEN4 is a MEN-like syndrome with a phenotypic overlap of both MEN1 and MEN2.

OUTRAS DOENÇAS (2)
multiple endocrine neoplasia type 4multiple endocrine neoplasia type 1
HGNC:1785UniProt:P46527
CDKN2BCyclin-dependent kinase 4 inhibitor BCandidate gene tested inTolerante
FUNÇÃO

Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (5)
Cyclin D associated events in G1Senescence-Associated Secretory Phenotype (SASP)Oncogene Induced SenescenceOxidative Stress Induced SenescenceSMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
OUTRAS DOENÇAS (2)
familial melanomamultiple endocrine neoplasia type 1
HGNC:1788UniProt:P42772

Medicamentos aprovados (FDA)

1 medicamento encontrado nos registros da FDA americana.

💊 Famotidine (FAMOTIDINE)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

1,198 variantes patogênicas registradas no ClinVar.

🧬 MEN1: NM_001370259.2(MEN1):c.1186-1G>C ()
🧬 MEN1: NM_001370259.2(MEN1):c.767T>G (p.Leu256Arg) ()
🧬 MEN1: NM_001370259.2(MEN1):c.1009G>A (p.Ala337Thr) ()
🧬 MEN1: NM_001370259.2(MEN1):c.478dup (p.Ala160fs) ()
🧬 MEN1: NM_001370259.2(MEN1):c.361dup (p.Val121fs) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 2,436 variantes classificadas pelo ClinVar.

122
1827
487
Patogênica (5.0%)
VUS (75.0%)
Benigna (20.0%)
VARIANTES MAIS SIGNIFICATIVAS
MEN1: NM_001370259.2(MEN1):c.1186-1G>C [Likely pathogenic]
MEN1: NM_001370259.2(MEN1):c.445+15G>C [Uncertain significance]
MEN1: NM_001370259.2(MEN1):c.1367G>C (p.Arg456Pro) [Uncertain significance]
MEN1: NM_001370259.2(MEN1):c.1799T>C (p.Leu600Pro) [Uncertain significance]
MEN1: NM_001370259.2(MEN1):c.86G>T (p.Arg29Leu) [Uncertain significance]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
2Fase 21
·Pré-clínico6
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 8 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Neoplasias endócrinas múltiplas tipo 1

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

6 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

192 ensaios clínicos encontrados, 8 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
918 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 918

#1

18F-Choline PET/CT Localization in a 20-Year Experience of Re-Operative Parathyroidectomy.

World journal of surgery2026 Mar 23

Reoperative parathyroidectomy is necessary in up to 10% of patients with persistent or recurrent primary hyperparathyroidism. Accurate preoperative localization is critical for surgical success and minimizing complications. Conventional imaging methods often yield inconclusive or false-negative results in this challenging patient population. To evaluate the diagnostic accuracy and clinical utility of 18F-fluorocholine positron emission tomography/computed tomography imaging compared to traditional imaging modalities of neck ultrasonography and 99mTechnetium-sestamibi parathyroid scintigraphy in patients undergoing reoperative parathyroidectomy. Retrospective cohort study of patients undergoing reoperative parathyroidectomy over a 20-year period (2005-2025). Localization imaging modalities, operative approaches, intraoperative parathyroid hormone monitoring, and surgical outcomes were analyzed. Single tertiary referral center specializing in endocrine surgery with a high-volume parathyroidectomy practice. 114 consecutive adult patients (aged ≥ 18 years) were included who underwent 124 reoperative parathyroidectomy operations for biochemically confirmed persistent or recurrent primary hyperparathyroidism. Patients were included if there was lithium-associated hyperparathyroidism or multiple endocrine neoplasia type 1 syndrome. Primary outcome included localization detection rates of imaging modalities performed. Secondary outcomes included type of surgical approach utilized, cause of failure from the primary operation, intraoperative parathyroid hormone monitoring response, biochemical cure rate, and surgical complications. 18F-fluorocholine positron emission tomography/computed tomography demonstrated a detection rate of 95.2%, outperforming 11C-methionine positron emission tomography/computed tomography (63.6%), fludeoxyglucose-positron emission tomography/computed tomography (50.0%), and neck ultrasonography (21.6%). In 90.5% of cases with negative or inconclusive conventional imaging, 18F-fluorocholine positron emission tomography/computed tomography accurately localized pathological parathyroid gland(s). A focused surgical approach (sternotomy or unilateral cervicotomy) was feasible in 87.1% of patients. Appropriate intraoperative parathyroid hormone monitoring decline was associated with a 95.8% biochemical cure rate. Complication rates were low, with vocal cord palsy in 0.8% and long-term hypoparathyroidism requiring calcium supplementation in 2.4%. 18F-fluorocholine positron emission tomography/computed tomography offers superior localization accuracy and a favorable radiation profile compared to conventional imaging options, supporting its use as a first-line modality in reoperative parathyroidectomy. Its application enables focused surgical interventions with high cure rates and low morbidity.

#2

Surgical Management of Zollinger-Ellison Syndrome in Multiple Endocrine Neoplasia Type 1 an AFCE and GTE Cohort Study. (Association Francophone de Chirurgie Endocrinienne and Groupe d'étude des Tumeurs Endocrines).

World journal of surgery2026 Mar 20

To describe surgical indications, procedures and outcomes in patients operated for Zollinger-Ellison syndrome (ZES) in multiple endocrine neoplasia type 1 (MEN1) using a large nationwide cohort. Management of ZES in MEN1 remains controversial. All patients with ZES diagnosed through the MEN1 AFCE/GTE network from 1985 to 2015. Among 233 ZES patients, 66 (28%) were operated for ZES-related gastrinomas. Thirty-three (51%) procedures aimed to remove gastrinomas and associated pancreatic neuroendocrine tumors (pNET(s)) with appropriate resection. Thirty-two procedures (49%) aimed to remove gastrinomas alone (ZES group). Survival was decreased in patients metastatic at ZES diagnosis (p < 0.001). Fifteen-year survival among non-metastatic patients was not significantly better in operated patients (82% vs. 70%, p = 0.2). Perioperative mortality was nil. Metastatic lymph nodes were found in 30/42 lymphadenectomies (71%). The choice between pancreaticoduodenectomy versus duodenal focused surgery in the ZES group was associated with pre-operative detection of adenopathies (p > 0.001), leading to more frequent lymphadenectomies (p < 0.01). Previous pancreatic surgeries (30%) may have influenced the choice of ZES procedures. Gastrin levels were more frequently normalized when the duodenum and the head of pancreas were removed versus more localized duodenal surgeries (p < 0.01). The high rate of invaded nodes in lymphadenectomies in MEN1 patients operated for ZES, the absence of operative mortality, and the decreased survival in metastatic patients are indirect arguments for surgery. Pancreaticoduodenectomy may be indicated in young and fit individuals to better control hypergastrinemia and to prevent metastatic progression in the ZES group. Gastrinoma removal is justified when associated with large pNETs.

#3

[Multiple endocrine neoplasia syndrome type 1: analysis of data from 102 patients from 43 families in the population of the Russian Federation].

Problemy endokrinologii2026 Mar 07

 Multiple endocrine neoplasia syndrome type 1 (MEN-1) is a rare, autosomal dominant disorder resulting from inactivating mutations in the MEN1 gene. It demonstrates high penetrance, with the "classic triad" of manifestations comprising primary hyperparathyroidism (PHPT), gastrointestinal neuroendocrine neoplasms (NEN), and pituitary adenomas. Diagnosis relies on clinical, familial, and genetic criteria. However, significant phenotypic variability and the lack of a clear genotype-phenotype correlation complicate early diagnosis.  To investigate the clinical-epidemiological, laboratory-instrumental, and genetic characteristics of familial MEN-1 in the Russian population.  We conducted a single-center, single-stage study (2015-2025) at the Endocrinology Research Centre enrolling 102 genetically confirmed MEN-1 patients from 43 families. Participants were stratified by age at PHPT onset (≤18 years, 19-40 years, and &gt;40 years) and MEN1 mutation type/location. We compared groups using calcium-phosphorus metabolism parameters, disease progression patterns, PHPT surgical outcomes, and genotype-phenotype correlations.  Cohort baseline characteristics (sex, manifestations) were comparable (p&gt;0,05), but we observed significant differences in NEN onset age (p&lt;0,001) and a trend toward higher pituitary adenoma prevalence (p=0,003). Exon 10 mutation were associated with a 7,7-fold increased pituitary adenoma risk (OR=7,7; p=0,006), though mutation type did not predict broader phenotype. Groups did not differ in multiglandular involvement, surgical outcomes, or histopathology (p&gt;0,05).  MEN-1 exhibits marked clinical heterogeneity in the Russian population, with exon 10 mutations significantly increasing pituitary adenoma risk. Early-onset PHPT predicts earlier NEN and pituitary adenoma development. These findings support proactive genetic screening and risk-stratified monitoring for MEN-1 families. ОБОСНОВАНИЕ. Синдром множественных эндокринных неоплазий 1 типа (МЭН-1) — редкое аутосомно-доминантное заболевание, обусловленное инактивирующими мутациями в гене MEN1. МЭН-1 характеризуется высокой пенетрантностью; к «классической триаде» проявлений синдрома относятся первичный гиперпаратиреоз (ПГПТ), нейроэндокринные неоплазии (НЭН) желудочно-кишечного тракта (ЖКТ) и аденомы гипофиза. Диагноз устанавливается на основании клинических, семейных и генетических критериев, однако фенотипическая вариабельность и отсутствие четкой генотип-фенотипической корреляции затрудняют раннюю диагностику заболевания. ЦЕЛЬ. Охарактеризовать клинико-эпидемиологические, лабораторно-инструментальные и генетические особенности семейных форм МЭН-1 в Российский Федерации. МАТЕРИАЛЫ И МЕТОДЫ. На базе ФГБУ «НМИЦ эндокринологии им. академика И.И. Дедова» Минздрава России проведено одноцентровое одномоментное исследование (102 пациента с генетически верифицированным МЭН-1 из 43 семей) за период 2015–2025 гг. Пациенты были разделены 3 группы в зависимости от возраста манифестации ПГПТ — в большинстве случаев «первого» компонента заболевания: ≤18 лет, 19–40 лет и >40 лет. Кроме того, все пациенты были сгруппированы в зависимости от типа и локализации мутации в гене MEN1. Проведен сравнительный анализ независимых групп и подгрупп по основным показателям кальций-фосфорного обмена, характеристикам проявлений, течению и исходам хирургического лечения ПГПТ, проанализирована генотип-фенотипическая корреляция МЭН-1. РЕЗУЛЬТАТЫ. Группы пациентов с МЭН-1 были сопоставимы по основным характеристикам (пол, первый компонент, другие проявления синдрома; p>0,05), однако выявлены значимые различия в возрасте манифестации НЭН (p<0,001) и тенденция для аденом гипофиза (p=0,003). При анализе генетических данных мы обнаружили ассоциацию между мутацией в 10-м экзоне гена MEN1 и риском развития аденом гипофиза (ОР=7,7; p=0,006), в то время как тип мутации никак не определял фенотип МЭН-1. Группы не различались по множественному характеру поражения околощитовидных желез (ОЩЖ), хирургическим исходам ПГПТ, а также гистологическим характеристикам образований ОЩЖ (p>0,05). ЗАКЛЮЧЕНИЕ. Анализ семейных форм МЭН-1 в российской популяции подтвердил высокую клиническую гетерогенность синдрома, включая ассоциацию мутаций в 10-м экзоне гена MEN1 с повышенным риском аденом гипофиза. У пациентов с манифестацией ПГПТ в более молодом возрасте отмечалось более раннее развитие НЭН ЖКТ и аденом гипофиза. Результаты исследования подтверждают необходимость раннего генетического скрининга и индивидуального мониторинга пациентов с МЭН-1, а также их родственников.

#4

Challenges and unmet needs of [18F]fluorocholine PET in hyperparathyroidism: A framework for refining current practice and advancing parathyroid imaging.

European journal of nuclear medicine and molecular imaging2026 Mar 13

The advent of [18F]fluorocholine (FCH) positron emission tomography (PET)/computed tomography (CT) or magnetic resonance (MR) imaging has enhanced the diagnostic performance of preoperative imaging in patients with primary and renal hyperparathyroidism (HPT) during the past decade [1, 2]. Numerous studies and meta-analyses have confirmed the excellent performance of FCH PET, including in complex cases (i.e., inconclusive or negative results on parathyroid scintigraphy, recurrence, renal hyperparathyroidism (HPT), multiple endocrine neoplasia type 1 (MEN1)-related pHPT), with diagnostic accuracy consistently exceeding 95% in larger studies [3-11]. As a result, when available, FCH PET is a widely accepted first-line modality for primary and renal HPT [10]. Moreover, FCH PET offers several advantages over parathyroid scintigraphy, such as a lower radiation dose burden (especially if PET/MR is used) [12, 13], shorter acquisition times, and sustained cost-effectiveness [14-17]. Despite these advantages, there are several unmet needs that remain to be addressed. This editorial explores the remaining challenges associated with the use of FCH PET and underscores the need for close interdisciplinary collaboration among nuclear medicine physicians, endocrinologists, and surgeons to further optimize diagnostic and therapeutic strategies and address existing clinical gaps.

#5

In-depth Genetic and Molecular Characterization of Unilateral Coexisting Adrenal Cortical Adenoma and Carcinoma in the Context of MEN1 Syndrome.

Endocrine pathology2026 Mar 10

Adrenal lesions often occur in patients with multiple endocrine neoplasia type 1 (MEN1), mostly adrenal cortical adenomas (ACAs), although the frequency of adrenal cortical carcinomas (ACCs) is higher than in the general population. The coexistence of benign and malignant masses has seldom been documented, leaving open the question of ACC progression from benign forms. We report a comprehensive genetic characterization of three adrenal cortical tumor samples obtained from a familial MEN1 patient, operated for the rapid progression of an initially stable nonfunctional adrenal incidentaloma. Histologically, the tumor consisted of a small ACA contiguous to a large ACC, which subsequently relapsed. Exome sequencing of ACC, ACA and recurrence evidenced a MEN1 loss of heterozygosity (LOH) in ACC but not in ACA, where, however, a second hit driven by alternative mechanisms could not be excluded. The majority of the ACA variants were found to co-occurred in ACC (n = 36/42) and were benign, except for two of unknown significance in KANK1 and REN genes, described as associated with renal cancer. Among variants shared between ACC and its recurrence (n = 69), 11 were Tier III, while 2 affecting TP53 and NF1 genes were pathogenic. Bioinformatic clonal evolution analysis identified one clone - characterized by TP53 and NF1 mutations - absent in ACA but present in ACC and recurrence, as well as 2 clones shared between ACA and ACC but lost in the recurrence. In conclusion, comparative Whole Exome Sequencing (WES) analysis of three adrenal tumors in a MEN1 patient suggests a possible relationship between malignant and benign lesions occurring in MEN1 patients, without, however, demonstrating any causal adenoma-to-carcinoma progression driven by MEN1 LOH. Overall, these data further suggest an increased risk of MEN1 patients to develop adrenocortical malignancy.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC1.112 artigos no totalmostrando 195

2026

18F-Choline PET/CT Localization in a 20-Year Experience of Re-Operative Parathyroidectomy.

World journal of surgery
2026

Surgical Management of Zollinger-Ellison Syndrome in Multiple Endocrine Neoplasia Type 1 an AFCE and GTE Cohort Study. (Association Francophone de Chirurgie Endocrinienne and Groupe d'étude des Tumeurs Endocrines).

World journal of surgery
2026

[Multiple endocrine neoplasia syndrome type 1: analysis of data from 102 patients from 43 families in the population of the Russian Federation].

Problemy endokrinologii
2026

Challenges and unmet needs of [18F]fluorocholine PET in hyperparathyroidism: A framework for refining current practice and advancing parathyroid imaging.

European journal of nuclear medicine and molecular imaging
2026

In-depth Genetic and Molecular Characterization of Unilateral Coexisting Adrenal Cortical Adenoma and Carcinoma in the Context of MEN1 Syndrome.

Endocrine pathology
2026

Multiple endocrine neoplasia with an atypical clinical course and a MEN1 gene variant of uncertain pathogenicity: A case report.

Medicine
2026

Corrigendum to: "Health-related quality of life of Multiple Endocrine Neoplasia type 1 patients: A mixed methods systematic review" [Eur J Cancer, Vol. 227, 9 September 2025, 115671].

European journal of cancer (Oxford, England : 1990)
2026

Redefining Pituitary Neuroendocrine Tumors in MEN1: Prevalence, Clinical Behavior, and Implications for Long-Term Surveillance.

Current oncology (Toronto, Ont.)
2026

Multiple endocrine neoplasia type 1 with MEN1 c.652C>T (p.Arg218Trp): variant reclassified to likely pathogenic.

JCEM case reports
2026

Two novel multiple endocrine neoplasia type 1 variants caused thymic neuroendocrine tumor: a case report.

Hereditary cancer in clinical practice
2026

Ventricular fibrillation triggered by recurrent hypoglycemia in a patient with insulinoma associated with MEN1: case report and review of literature.

Endocrine journal
2025

Rank-based learning: a novel high-throughput algorithm resilient to missing data and effective for datasets with small sample size.

Briefings in bioinformatics
2026

Case Report: Investigation and characterization of a multiple endocrine neoplasia type 1 case and its pedigree.

Frontiers in endocrinology
2026

Distinct epigenetic aging in sporadic and hereditary neuroendocrine neoplasms.

Clinical epigenetics
2026

Lipid synthesis seems to drive proliferation in Men1 mouse adrenals and human adrenocortical cell lines.

Endocrine-related cancer
2026

Surgical and Oncologic Outcomes After Pancreatectomy for Pancreatic Neuroendocrine Tumor in Multiple Endocrine Neoplasia Type 1 and von Hippel-Lindau Syndrome: A Large, Multi-Institutional, Cohort Study.

Journal of the American College of Surgeons
2026

Insulin Resistance Among Patients With Multiple Endocrine Neoplasia Type 1: A Systemic Review and Meta-Analysis.

AACE endocrinology and diabetes
2026

Metformin suppresses MEN1-associated pancreatic and pituitary neuroendocrine tumors: evidence from mouse models and clinical data.

Endocrine-related cancer
2026

Blood-Based Immunoglobulin-Bound Neoantigen Signatures Associated with Multiple Endocrine Neoplasia Type 1-Related Duodenopancreatic Neuroendocrine Tumor Progression.

Journal of the American College of Surgeons
2025

Cardiac Tamponade As the Initial Presentation of a Thymic Neuroendocrine Tumour: A Case Report.

CJC open
2025

Multiple Endocrine Neoplasia Type 1 Presenting as Recurrent Overt Gastrointestinal Bleeding and Ulceration: A Diagnostic Challenge.

Cureus
2026

Radiological Surveillance for Pituitary Adenomas in Multiple Endocrine Neoplasia Type 1: A Longitudinal Cohort Study.

The Journal of clinical endocrinology and metabolism
2026

Concept of neuroendocrine neoplasms of all organs with a focus on grading, subtyping.

Virchows Archiv : an international journal of pathology
2025

Ultrasound and Scintigraphy for Preoperative Localization in Primary Hyperparathyroidism: A Single-Center Experience.

Cureus
2026

Multiple endocrine neoplasia type 1 syndrome due to novel Alu insertion.

Cancer genetics
2025

New directions in MEN1 management: navigating the new clinical practice guidelines.

European journal of endocrinology
2025

[The 514th case: urinary stone excretion, elevated blood glucose, pancreatic mass,and co-secretion of multiple hormones].

Zhonghua nei ke za zhi
2026

Delay in Diagnosis of Thyroid-Stimulating Hormone-Secreting Pituitary Adenomas: Clinical and Endocrinological Profiles from a Retrospective Cohort Study.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
2025

Case Report: Novel likely pathogenic MEN1 mosaic mutation in the family with MEN-1 syndrome.

Frontiers in endocrinology
2025

The clinical challenge of MEN1 phenocopies: insights from a multicentric national retrospective study.

Journal of endocrinological investigation
2026

Role of MEN1 mutations on postoperative outcomes of patients with multiple endocrine neoplasia type 1-related primary hyperparathyroidism: a single center experience.

Journal of endocrinological investigation
2025

Population-Based Evidence of Familial Clustering in Pulmonary Carcinoid Tumors: Insights From the Utah Population Database.

Cureus
2025

A Case of Pediatric Pancreatic Insulinoma Diagnosed 4 Years after the Onset.

Surgical case reports
2025

Unusual Dual Brain Tumor Morphologies in an MEN1 Patient: A Case Report of Diagnostic Challenges and Methylation Insights.

International journal of molecular sciences
2025

Bilateral and recurrent adrenocortical carcinoma in MEN1: a case report and review of the literature.

Endocrine oncology (Bristol, England)
2025

A 14-yr-old boy with a pathogenic MEN1 variant was diagnosed with asymptomatic insulinoma during routine follow-up.

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
2025

MEN1-Related Neuroendocrine Tumors Show c-MET Overexpression.

Journal of the Endocrine Society
2025

Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study.

Nuklearmedizin. Nuclear medicine
2025

Targeting menin in lysine methyltransferase 2A/nucleophosmin-mutated leukemia: A novel strategy from epigenetic dysregulation to clinical therapy (Review).

Oncology letters
2025

68Ga-DOTA-TATE PET/CT improves accuracy and guides management in multiple endocrine neoplasia type 1 (MEN-1) patients with suspected duodeno-pancreatic neuroendocrine tumours.

Endocrine oncology (Bristol, England)
2026

Risk Factors for Pituitary Adenoma Development in Multiple Endocrine Neoplasia Type 1: A Nationwide Study of 240 Cases.

The Journal of clinical endocrinology and metabolism
2025

Extent of Surgical Resection and Predictors of Outcomes in MEN1-related Hyperparathyroidism: A Systematic Review and Meta-analysis.

The Journal of clinical endocrinology and metabolism
2025

Approach to the Patient With Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1.

The Journal of clinical endocrinology and metabolism
2025

Gastrointestinal surveillance in patients with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome.

Scandinavian journal of gastroenterology
2025

Health-related quality of life of Multiple Endocrine Neoplasia Type 1 patients: A mixed methods systematic review.

European journal of cancer (Oxford, England : 1990)
2025

Familial MEN1 Syndrome with Atypical Renal Features and a Coexisting CLDN16 Variant: A Case Series.

Journal of clinical medicine
2025

Integrated 18F-FCH PET/4D-CT in a Case of Supernumerary Parathyroid Glandular Hyperplasia With Incidentally Detected Thymic NET.

Clinical nuclear medicine
2025

Multiple endocrine neoplasia type 1 with neuroglycopenic symptoms with a novel heterozygous MEN1 gene mutation.

World journal of surgical oncology
2025

A Long-Term Follow-Up of 2 Cases of Subclinical Acromegaly.

AACE endocrinology and diabetes
2025

Novel germline likely pathogenic frameshift variant of the MEN1 gene contributes to multiple endocrine neoplasia type 1: a case report with review of literature.

Endocrine journal
2025

The role of thymectomy during parathyroidectomy in multiple endocrine neoplasia type 1-associated hyperparathyroidism: a systematic review and meta-analysis.

World journal of surgical oncology
2025

ASO Author Reflections: Patient Selection and Technique for Robotic Spleen-Preserving Distal Pancreatectomy.

Annals of surgical oncology
2025

Cyclic Cushing syndrome associated with cadherin-23 and multiple endocrine neoplasia type 1 gene mutations accompanied by bilateral primary papillary thyroid carcinoma.

Polish archives of internal medicine
2025

A Case of Advanced Renal Cell Carcinoma With Concomitant Development of Multiple Endocrine Neoplasia Type 1 That Affected Treatment Progress With Immunotherapy.

IJU case reports
2025

Epidemiology and clinical outcomes of clinically suspected multiple endocrine neoplasia type 1 in South Korea: a nationwide cohort study.

Frontiers in endocrinology
2025

68 Ga-DOTATATE PET/CT-Guided Surgical Resection for Complete Remission of Multifocal Insulinomas in a Father and Son With MEN1 Syndrome.

Clinical nuclear medicine
2026

Circulating Gene Expression Assay as a Diagnostic and Prognostic Biomarker for Pancreatic Neuroendocrine Tumors in MEN1.

The Journal of clinical endocrinology and metabolism
2025

Pituitary incidentaloma: a Pituitary Society international consensus guideline statement.

Nature reviews. Endocrinology
2025

Robotic Spleen-Preserving Distal Pancreatectomy for Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1.

Annals of surgical oncology
2025

Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice.

The lancet. Diabetes &amp; endocrinology
2025

Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis.

The lancet. Diabetes &amp; endocrinology
2025

68 Ga-Exendin-4 PET/CT Enables Identification of Multiple and Ectopic Insulinoma in a Patient With Multiple Endocrine Neoplasia 1.

Clinical nuclear medicine
2025

Serums miR-24-3p and miR-1301-3p as Potential Biomarkers in MEN1 Syndrome.

International journal of molecular sciences
2025

Importance of understanding a diagnostic-treatment algorithm for primary hyperparathyroidism-induced acute pancreatitis during pregnancy.

World journal of gastroenterology
2026

Pancreatic Neuroendocrine Tumor Leading to a Diagnosis of Multiple Endocrine Neoplasia Type 1.

DEN open
2025

Double mutation for multiple endocrine neoplasia associated with congenital adrenal hyperplasia.

Endocrinology, diabetes &amp; metabolism case reports
2025

Successful treatment of metachronous insulinoma in a patient with multiple endocrine neoplasia type 1 syndrome.

Polish archives of internal medicine
2025

Chromogranin a and pancreatic polypeptide are not suitable for the screening of pancreatic neuroendocrine tumors in MEN1 - a long-term follow-up study.

Endocrine
2025

A Pituitary Macroadenoma Cosecreting Prolactin and Growth Hormone in a Patient With Multiple Endocrine Neoplasia Type 4.

JCEM case reports
2025

A neural substrate of comorbid depressive symptoms in alcohol use.

Molecular psychiatry
2025

Case Report: A novel likely pathogenetic variant of the MEN1 gene in multiple endocrine neoplasia type 1.

Frontiers in endocrinology
2025

Recurrence of malignant insulinoma in the context of multiple endocrine neoplasia type 1: a case report.

Journal of surgical case reports
2025

Clinical phenotypes and genetic screening in hereditary primary hyperparathyroidism: A single-center case series.

Annales d'endocrinologie
2025

An Updated Perspective of the Clinical Features and Parathyroidectomy Impact in Primary Hyperparathyroidism Amid Multiple Endocrine Neoplasia Type 1 (MEN1): Focus on Bone Health.

Journal of clinical medicine
2025

Multimodal Imaging Approach to MEN-1 Syndrome-Associated Tumors.

Diagnostics (Basel, Switzerland)
2025

Benefit of splenectomy in distal pancreatectomy for neuroendocrine tumours: multicentre retrospective study.

BJS open
2025

Oncocytic subtype of well differentiated neuroendocrine tumor: clinicopathologic and molecular associations of a cohort diagnosed on fine needle aspiration (FNA).

Journal of the American Society of Cytopathology
2025

Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations.

JCO oncology advances
2025

Characterization, Prognosis, and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE, ENDOCAN RENATEN, and RYTHMIC Networks.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
2025

Predictors of Mortality in Patients With Multiple Endocrine Neoplasia Type 1.

Clinical endocrinology
2025

Heterozygous Men1(+/T) Knockout Mice Do Not Develop Bronchopulmonary Neuroendocrine Hyperplasia or Neoplasia but Bronchial Adenocarcinoma.

Advances in respiratory medicine
2025

Highlights from the AACE Consensus Statement on Multiple Endocrine Neoplasia Type 1: A Patient's Perspective.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2025

Importance of early detection in multiple endocrine neoplasia type 1: Clinical insights and future directions.

World journal of gastrointestinal oncology
2025

American Association of Clinical Endocrinology Consensus Statement on Management of Multiple Endocrine Neoplasia Type 1.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2024

Forearm Auto-Transplantation of Adenomatous Parathyroid Tissue to Prevent Post-Surgical Hypoparathyroidism: A Case Report.

West African journal of medicine
2025

A Novel Mutation in a Family With Multiple Endocrine Neoplasia Type 1 and Aggressive Pancreatic Neuroendocrine Tumors.

AACE clinical case reports
2025

Prognostic value of clinical parameters and exosomal lncRNA NEAT1_1 in MEN1-related non-functioning pancreatic neuroendocrine tumors.

Journal of neuroendocrinology
2025

Primary hyperparathyroidism during pregnancy: ultrasound as an accurate preoperative localization imaging modality.

Orphanet journal of rare diseases
2025

[Microwave ablation for primary hyperparathyroidism related to multiple endocrine neoplasia type 1 in 3 cases of a family].

Zhonghua nei ke za zhi
2025

Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis.

Seminars in cancer biology
2025

Bone Mineral Density Changes in Multiple Endocrine Neoplasia Type 1: A Systematic Review and Meta-Analysis of Prevalence and Parathyroidectomy Outcomes.

The archives of bone and joint surgery
2025

Multiple Endocrine Neoplasia Type 1 (MEN1) Syndrome Clinical Presentation and the Role of Newer Functional Imaging in the Diagnosis and Management: A Case Report.

Cureus
2025

Multiple endocrine neoplasia type 1 in childhood and description of a novel variant.

Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo
2025

A Five-Year Journey to Diagnosis: Resolving Persistent Hypoglycemia Through Successful Insulinoma Resection-A Case Report.

Clinical case reports
2025

A Novel Multiple Endocrine Neoplasia Type 1 Gene Variant Found in Scalp Pulmonary Neuroendocrine Tumor Metastasis.

JCEM case reports
2025

Serendipitous Discovery and Characterization of Two Different Pathologies on 68 Ga-DOTATATE and 68 Ga-Exendin PET/CT in a Patient With Hyperinsulinemic Hypoglycemia Leading to Diagnosis of MEN-1.

Clinical nuclear medicine
2025

A Review for the Clinician: Classifications, Genetics, and Treatment for Neuroendocrine Neoplasms of the Thymus (Thymic Carcinoids).

Neuroendocrinology
2025

The Influence of the Clinical, Therapeutic and Socio-Personal Profile on the Quality of Life of Patients With Multiple Endocrine Neoplasia Type 1.

World journal of surgery
2025

Management of primary hyperparathyroidism in MEN1: From initial subtotal surgery to complex treatment of the remaining gland.

Annales d'endocrinologie
2025

Mirrored Metastatic Neuroendocrine Tumor in a Mother-Daughter Duo With Mutations in the MEN1 Gene.

Clinical nuclear medicine
2025

A novel likely pathogenic germline variant in CDKN1B in a patient with MEN4 and medullary thyroid cancer.

Familial cancer
2025

Hsp70 incompletely disaggregates misfolded K488X-menin to promote tumourigenesis in a family with multiple endocrine neoplasia type 1.

Cellular signalling
2025

Rare Combination of Multiple Endocrine Neoplasia 1 with Medullary Thyroid Carcinoma and Clinical Value of 68 Ga-DOTATATE PET/CT in Diagnosing Different Lesions and Exploring Theranostic Strategy.

World journal of nuclear medicine
2025

Multiple endocrine neoplasia type 1: Early diagnosis is very important.

World journal of gastroenterology
2025

The natural course of cystic pancreatic neuroendocrine tumours in MEN1.

Endocrine oncology (Bristol, England)
2024

[A Case of Type Ⅲ Gastric Neuroendocrine Tumor and Gastric Cancer Coexisting in the Same Lesion].

Gan to kagaku ryoho. Cancer &amp; chemotherapy
2025

Genotype-phenotype correlation in multiple endocrine neoplasia type 1.

JCI insight
2025

Multiple Endocrine Neoplasia Type 1 With Adrenal Cortical Adrenocortical Carcinoma: A 25-Year Follow-Up and Family Report.

JCEM case reports
2025

Elevated levels of circulating microbial-associated uremic toxins are associated with metastatic duodenopancreatic neuroendocrine tumors in patients with Multiple Endocrine Neoplasia Type 1.

Cancer letters
2025

Association of primary hyperparathyroidism with pituitary adenoma and management issues.

Best practice &amp; research. Clinical endocrinology &amp; metabolism
2025

A Novel and Rare Pathogenic Gene Variant in 2 Patients With Multiple Endocrine Neoplasia Type 1 (MEN-1) Syndrome.

JCEM case reports
2025

Mixed neuroendocrine non-neuroendocrine neoplasm combining neuroendocrine tumor with hepatocellular carcinoma in the context of multiple endocrine neoplasia type 1.

Clinics and research in hepatology and gastroenterology
2025

Progress report on multiple endocrine neoplasia type 1.

Familial cancer
2025

Adolescent primary hyperparathyroidism.

Best practice &amp; research. Clinical endocrinology &amp; metabolism
2025

Chapter 6: Syndromic primary hyperparathyroidism.

Annales d'endocrinologie
2024

Up-to-Date Imaging for Parathyroid Tumor Localization in MEN1 Patients with Primary Hyperparathyroidism: When and Which Ones (A Narrative Pictorial Review).

Diagnostics (Basel, Switzerland)
2025

Genotype-Phenotype Correlations in the Hyperparathyroidism-Jaw Tumor Syndrome.

The Journal of clinical endocrinology and metabolism
2024

[Review of Multiple Endocrine Neoplasia Type 1 Based on a Clinical Case].

Revista medica de Chile
2025

Potential benefits of intraoperative parathyroid autofluorescence imaging in a patient with multiple endocrine neoplasia type 1 and hyperparathyroidism - A case report.

International journal of surgery case reports
2025

Intraoperative indocyanine green with ultrasound-guided localization as prodigious adjuncts explicating negative margin in functional insulinoma: A case report.

International journal of surgery case reports
2024

Case report: A 51-year-old diabetic patient with primary bilateral macronodular adrenal hyperplasia and primary hyperparathyroidism.

Frontiers in endocrinology
2024

Genotype-negative multiple endocrine neoplasia type 1 with prolactinoma, hyperparathyroidism, and subclinical Cushing's syndrome accompanied by hyperglycemia: a case report.

Frontiers in endocrinology
2025

Genotype-based prognosis prediction for MEN1-Related pancreatic neuroendocrine tumors in Korean patients a single-center retrospective study.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
2024

Sarcomas arising in MEN1 patients: demonstrating LOH of the MEN1 locus and loss of menin expression.

Familial cancer
2024

Extra-adrenal adrenocortical cancer associated with multiple endocrine neoplasia type 1.

Endocrinology, diabetes &amp; metabolism case reports
2024

Targeting Menin in Acute Myeloid Leukemia: Therapeutic Advances and Future Directions.

Cancers
2025

Screening and surveillance practices for Multiple Endocrine Neoplasia type 1-related Neuroendocrine Tumours in European Neuroendocrine Tumor Society Centers of Excellence (ENETS CoE)-An ENETS MEN1 task force questionnaire study.

Journal of neuroendocrinology
2024

Paradoxical cerebral embolism caused by patent foramen ovale in a patient with multiple endocrine neoplasia type 1 and severe primary hyperparathyroidism.

BMJ case reports
2024

Improving early diagnosis of multiple endocrine neoplasia type 1 by assessing the gastrointestinal symptoms, hypercalcemia, and elevated serum gastrin.

World journal of gastroenterology
2024

Bone mineral density over ten years after primary parathyroidectomy in multiple endocrine neoplasia type 1.

JBMR plus
2025

Adrenocortical tumors and hereditary syndromes.

Expert review of endocrinology &amp; metabolism
2024

Prognosis after curative resection of non-metastatic pancreatic neuroendocrine tumors: a retrospective tertiary center study.

Annals of gastroenterology
2024

Genetic Landscape and Clinical Manifestations of Multiple Endocrine Neoplasia Type 1 in a Korean Cohort: A Multicenter Retrospective Analysis.

Endocrinology and metabolism (Seoul, Korea)
2024

Molecular Pathophysiology of Parathyroid Tumorigenesis-The Lesson from a Rare Disease: The "MEN1 Model".

International journal of molecular sciences
2024

Analysis of Bone Phenotype Differences in MEN1-Related and Sporadic Primary Hyperparathyroidism Using 3D-DXA.

Journal of clinical medicine
2025

Neuroendocrine Tumors and Survival Rates in Multiple Endocrine Neoplasia Type 1 Patients: Impact of Gender Difference.

Neuroendocrinology
2024

Long term outcomes of pituitary adenomas in Multiple Endocrine Neoplasia type 1: a nationwide study.

Frontiers in endocrinology
2024

Diagnosis and management of pituitary adenomas in children and adolescents.

European journal of endocrinology
2024

Case report: Novel germline c.587delA pathogenic variant in familial multiple endocrine neoplasia type 1.

Frontiers in endocrinology
2024

First reported case of multiple endocrine neoplasia type 1 in an Australian Aboriginal.

Endocrinology, diabetes &amp; metabolism case reports
2025

Choroidal melanoma in a patient with multiple endocrine neoplasia type 1.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
2025

Pituitary Neuroendocrine Tumors in Multiple Endocrine Neoplasia.

Endocrinology and metabolism (Seoul, Korea)
2024

68Ga-DOTATATE PET/CT: How is it reliable in imaging of cases having clinical suspicion of insulinomas?

European journal of radiology
2024

Case report: Comprehensive follow-up of a Colombian family carrying a novel MEN1 variant linked to a rare ACTH-producing pancreatic neuroendocrine carcinoma.

Frontiers in endocrinology
2024

Early detection of multiple endocrine neoplasia type 1: A case report.

World journal of gastroenterology
2024

Diagnostic Modalities, Management Considerations, and Outcomes of Insulinoma: A Case Series from a Tertiary Care Centre.

Indian journal of endocrinology and metabolism
2024

Sweet Saboteur: Insulinoma Presenting As Recurrent Hypoglycemic Seizures.

Cureus
2024

Multiple Endocrine Neoplasia Type 1, Type 2A, and Type 2B.

Primary care
2024

Management of Pancreatic Neuroendocrine Tumors: Surgical Strategies and Controversies.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2024

Menin signaling and therapeutic targeting in breast cancer.

Current problems in cancer
2024

Multiple endocrine neoplasia type 1 with MEN1 variant of unknown significance, in a patient after the diagnosed of pancreatic neuroendocrine neoplasia.

International cancer conference journal
2024

Turning Points in Cross-Disciplinary Perspective of Primary Hyperparathyroidism and Pancreas Involvements: Hypercalcemia-Induced Pancreatitis, MEN1 Gene-Related Tumors, and Insulin Resistance.

International journal of molecular sciences
2024

Phenotype and genotype of patients with multiple endocrine neoplasia type 1 studied in Argentina.

Medicina
2024

F18-Choline PET/CT or MIBI SPECT/CT in the Surgical Management of Primary Hyperparathyroidism: A Diagnostic Randomized Clinical Trial.

JAMA otolaryngology-- head &amp; neck surgery
2024

Hereditary Syndromes Associated with Pancreatic and Lung Neuroendocrine Tumors.

Cancers
2024

Role of Nutrition in the Management of Patients with Multiple Endocrine Neoplasia Type 1.

Nutrients
2024

Multiple Endocrine Neoplasia Type 1 Regulates TGFβ-Mediated Suppression of Tumor Formation and Metastasis in Melanoma.

Cells
2024

Successful management of a multiple endocrine neoplasia type 1-associated thymic neuroendocrine neoplasms with acute chest pain as initial symptom: A rare case report.

Clinical case reports
2024

Well-differentiated G1 and G2 pancreatic neuroendocrine tumors: a meta-analysis of published expanded DNA sequencing data.

Frontiers in endocrinology
2024

Multiple Endocrine Neoplasia Type 1.

Deutsches Arzteblatt international
2024

The importance of MLPA technique in the diagnosis of multiple endocrine neoplasia type 1.

Endocrinologia, diabetes y nutricion
2024

Middle-segment preserving pancreatectomy: a literature review and case report.

Langenbeck's archives of surgery
2024

Portuguese Pancreatic Club Perspectives on Pancreatic Neuroendocrine Neoplasms: Diagnosis and Staging, Associated Genetic Syndromes and Particularities of Their Clinical Approach.

GE Portuguese journal of gastroenterology
2024

The utility of gallium-68 positron emission tomography/computed tomography in MEN1-related parathyroid disease.

European journal of endocrinology
2024

The Medical and Surgical Management of Recurrent Multicenter Insulinomatosis Without Known Genetic Predisposition.

ACG case reports journal
2024

Pancreatic GHRHomas in Patients with or without Multiple Endocrine Neoplasia Type 1 (MEN 1) : An Analysis of 36 Reported Cases.

The journal of medical investigation : JMI
2024

A Cohort Study of CNS Tumors in Multiple Endocrine Neoplasia Type 1.

Clinical cancer research : an official journal of the American Association for Cancer Research
2024

Gastric neuroendocrine neoplasms.

Nature reviews. Disease primers
2024

Utility of Intraoperative Intrinsic Near-Infrared Imaging for Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1.

Cureus
2024

Menin Deficiency Induces Autism-Like Behaviors by Regulating Foxg1 Transcription and Participates in Foxg1-Related Encephalopathy.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2024

The lesion detection rate of Ga-68 DOTATATE PET/MR in multiple endocrine neoplasia type 1.

Journal of medical imaging and radiation oncology
2024

Genetic disorders and insulinoma/glucagonoma.

Endocrine-related cancer
2024

Primary Hyperparathyroidism in Young and Adolescents: Alike or Unlike Adult Hyperparathyroidism? - A Series from South India.

Indian journal of endocrinology and metabolism
2024

PDP type brain tumor in association with multiple endocrine neoplasia type 1.

Heliyon
2024

Heterogeneity of Multiple Pancreatic Neuroendocrine Tumors Identified by 68Ga-DOTANOC and 68Ga-Exendin-4 PET/CT in a Patient with Endogenous Hyperinsulinemic Hypoglycemia and Multiple Endocrine Neoplasia 1.

Neuroendocrinology
2025

Multifocal Insulinoma as the Unique Presenting Feature of Multiple Endocrine Neoplasia Type 1 in an Adolescent.

Hormone research in paediatrics
2024

[Comparative analysis of bone complications/manifestations in sporadic and MEN1-related primary hyperparathyroidism].

Problemy endokrinologii
2024

[Tumor predisposition in endocrinology - from MEN to FIPA].

Deutsche medizinische Wochenschrift (1946)
2023

PHPT with Pancreatitis: Atypical Presentation of PHPT.

Indian journal of endocrinology and metabolism
2024

Biliary Neuroendocrine Tumor.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2024

Multiple bronchial carcinoids associated with Cowden syndrome.

Endocrine
2024

Microwave ablation for recurrent primary hyperparathyroidism in four patients with multiple endocrine neoplasia type 1: a case series report.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
2024

[Plasma miRNA expression in patients with genetically confirmed multiple endocrine neoplasia type 1 syndrome and its phenocopies].

Problemy endokrinologii
2024

Genotype-histotype-phenotype correlations in hyperinsulinemic hypoglycemia.

Histology and histopathology
2024

A novel likely pathogenetic variant p.(Cys235Arg) of the MEN1 gene in multiple endocrine neoplasia type 1 with multifocal glucagonomas.

Journal of endocrinological investigation
2024

Beyond MEN1, When to Think About MEN4? Retrospective Study on 5600 Patients in the French Population and Literature Review.

The Journal of clinical endocrinology and metabolism
2024

Whole-Exome Screening and Analysis of Signaling Pathways in Multiple Endocrine Neoplasia Type 1 Patients with Different Outcomes: Insights into Cellular Mechanisms and Possible Functional Implications.

International journal of molecular sciences
2024

Syndromic MEN1 parathyroid adenomas consist of both subclonal nodules and clonally independent tumors.

Virchows Archiv : an international journal of pathology
2024

Familial multiple endocrine neoplasia type 1 with intrathoracic low-grade fibromyxoid sarcoma.

Surgical case reports
2024

Multiple endocrine neoplasia type 1 syndrome in a woman with hypoglycemia as the initial symptom.

Asian journal of surgery
2024

[Individualized approach for MEN1-associated duodenopancreatic neuroendocrine neoplasms].

Chirurgie (Heidelberg, Germany)
2024

[Multiple neuroendocrine tumors of the pancreas].

Pathologie (Heidelberg, Germany)
2024

Pancreatic Neuroendocrine Tumor in a Patient With Multiple Endocrine Neoplasia Type 4.

Mayo Clinic proceedings
2024

The risk of concurrent malignancies in patients with multiple endocrine neoplasia type 1: insights into clinical characteristics of those with multiple endocrine neoplasia type 1.

Journal of endocrinological investigation
2023

An aggressive cabergoline-resistant, temozolomide-responsive macroprolactinoma due to a germline SDHB pathogenic variant in the absence of paraganglioma or pheochromocytoma.

Frontiers in endocrinology
Ver todos os 1.112 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Neoplasias endócrinas múltiplas tipo 1.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Neoplasias endócrinas múltiplas tipo 1

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. 18F-Choline PET/CT Localization in a 20-Year Experience of Re-Operative Parathyroidectomy.
    World journal of surgery· 2026· PMID 41873061mais citado
  2. Surgical Management of Zollinger-Ellison Syndrome in Multiple Endocrine Neoplasia Type 1 an AFCE and GTE Cohort Study. (Association Francophone de Chirurgie Endocrinienne and Groupe d'&#xe9;tude des Tumeurs Endocrines).
    World journal of surgery· 2026· PMID 41862416mais citado
  3. [Multiple endocrine neoplasia syndrome type&#xa0;1: analysis of data from 102&#xa0;patients from 43 families in the population of the Russian Federation].
    Problemy endokrinologii· 2026· PMID 41834593mais citado
  4. Challenges and unmet needs of&#xa0;[18F]fluorocholine PET in hyperparathyroidism: A framework for refining current practice and&#xa0;advancing parathyroid imaging.
    European journal of nuclear medicine and molecular imaging· 2026· PMID 41820691mais citado
  5. In-depth Genetic and Molecular Characterization of Unilateral Coexisting Adrenal Cortical Adenoma and Carcinoma in the Context of MEN1 Syndrome.
    Endocrine pathology· 2026· PMID 41806143mais citado
  6. Associations of selected atypical non-neuroendocrine cancers with multiple endocrine neoplasia type 1.
    J Endocr Soc· 2026· PMID 41994491recente
  7. Extracellular signalling regulates gastrin transcription through site-specific phosphorylation and nuclear redistribution of Menin.
    bioRxiv· 2026· PMID 41993411recente
  8. Gastric neuroendocrine tumors: a comprehensive analysis of clinicopathological characteristics and survival outcomes from a reference center.
    Arq Bras Cir Dig· 2026· PMID 41983868recente
  9. A case of multiple type I endocrine neoplasia with gastrin-producing and glucagon-producing tumors successfully resected 18 years after insulinoma surgery.
    Clin J Gastroenterol· 2026· PMID 41945253recente
  10. A de novo MEN1 gene mutation in a 4-year-old boy with hypoglycemia: A case report and functional study.
    Cancer Genet· 2026· PMID 41936330recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:652(Orphanet)
  2. OMIM OMIM:131100(OMIM)
  3. MONDO:0007540(MONDO)
  4. GARD:3829(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Artigo Wikipedia(Wikipedia)
  8. Q3347154(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Neoplasias endócrinas múltiplas tipo 1
Compêndio · Raras BR

Neoplasias endócrinas múltiplas tipo 1

ORPHA:652 · MONDO:0007540
Prevalência
1-9 / 100 000
Herança
Autosomal dominant, Not applicable
CID-10
D44.8 · Neoplasia de comportamento incerto ou desconhecido com comprometimento pluriglandular
CID-11
Ensaios
8 ativos
Início
All ages
Prevalência
3.3 (Europe)
MedGen
UMLS
C0025267
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades